<DOC>
	<DOCNO>NCT01439971</DOCNO>
	<brief_summary>This study hypothesize study drug , PF-05280602 ( select dos ) safe administer subject severe Hemophilia A B without inhibitor demonstrate evidence hemostatic activity . This support preclinical finding hemophilic animal model .</brief_summary>
	<brief_title>Phase 1 Safety , Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant ( 813d ) In Adult Subjects With Hemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Male subject 18 &lt; 65 year old severe hemophilia A B without inhibitor FVIII FIX . Subjects willing able comply mandatory washout period prior screen prior dose 48 hour post dose . At screen include washout FIX 96 hour FVIII 72 houts . At dose include washout FIX 96 hour FVIII hemostatic agent 72 hour 48 hour post dose . Subjects must agree commit use highly effective method birth control time screen four week study drug administration . Presence bleed disorder addition hemophilia A B . Regular , concomitant therapy immunomodulating drug ( eg , intravenous immunoglobulin , routine systemic corticosteroid ) . History coronary artery disease , thrombolic disease diagnosis prothrombic disorder .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pharmacodynamic</keyword>
</DOC>